July 2021 - QuartzBio

July 29, 2021 — Translational research teams producing large datasets from biomarker-rich trials quickly face the next challenge: generating actionable insights from their data.

As we described in a previous case study, we have been working with many teams to enable deep mechanistic insight generation from their biomarker data to aid in signature development for selecting patients, predicting therapeutic response, and informing key development decisions.

Register for the webinar:

Title: Overcoming Clinical Sample Chaos: A Critical Step in Biomarker-Rich Trials

Duration: 45 minutes

You’ll see how a technology-enabled approach to clinical sample inventory management delivers:

Sample KPI dashboards for clinical, translational, & data management teams
Visibility into sample collection, processing, and consent status
Dynamic visualizations to quickly review expected vs actual sample status by patient, time point, and assay type

Multiple Labs, Multiple LIMS; Lack of Sponsor-Centric Visibility

In previous webinars and articles, we have analyzed key challenges facing biomarker operations. Given the expanding footprint of sites, labs, and biorepositories, there is no sole source where sponsors can find information on biospecimens and get insights into the whereabouts of a given specimen within its complex journey across sites, labs, and biorepositories.

In this post, we explore the relationship between “lab-centric” and “sponsor-centric” sample inventory reporting, and how connecting these inventories can keep data generation on track.